Add BrightSurf on Google Email

University of Colorado Anschutz


Varicella zoster virus can cause serious disease beyond chickenpox and shingles

Researchers uncover the broad range of diseases caused by varicella zoster virus, including neurological and systemic issues, and highlight the need for better understanding and treatment of its manifestations. The virus can reactivate years after chickenpox and affect every organ, making diagnosis and treatment challenging.

SourceUniversity of Colorado Anschutz·JournalNature Reviews Disease Primers·DateSep 3, 2026

University of Colorado Anschutz researchers identify an “energy addiction” in high-risk blood cancer stem cells

Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer. The study found that high-risk MDS stem cells are unusually dependent on nicotin...

SourceUniversity of Colorado Anschutz·JournalBlood Cancer Discovery·DateAug 10, 2026

Largest real-world study finds early flu antiviral treatment reduces ICU admissions in hospitalized children

A nationwide study published in JAMA Pediatrics found that early antiviral treatment with oseltamivir reduced ICU admissions and shortened hospital stays for children hospitalized with influenza. The study of over 7,000 pediatric hospitalizations showed a 31% lower likelihood of ICU admission among treated children.

SourceUniversity of Colorado Anschutz·JournalJAMA Pediatrics·DateAug 10, 2026

Study finds many Colorado jails still lack public opioid treatment policies despite state mandate

A study by CU Anschutz researchers found that nearly 40% of Colorado's 46 county jails lacked publicly available opioid treatment policies, hindering the implementation of life-saving treatments. The lack of transparency and comprehensive policies poses significant barriers to care for incarcerated people with opioid use disorder.

SourceUniversity of Colorado Anschutz·JournalHealth & Justice·TypeData/statistical analysis·DateAug 6, 2026

Crnic Institute landmark research paves the way for personalized medicine in Down syndrome

Researchers at the University of Colorado Anschutz Linda Crnic Institute discovered unique biological processes altered among individuals with Down syndrome who have different sets of co-occurring conditions. The findings mark an important step toward personalized treatment, enabling future targeted therapies and improved health outcomes.

SourceUniversity of Colorado Anschutz·JournalNature Communications·DateJul 23, 2026

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, form strategic alliance with Bayer to advance drug development and clinical trials

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, have formed a strategic alliance with Bayer to accelerate medical discovery and expand patient access to investigational therapies. Initial focus areas include oncology, cardiovascular disease, and cell and gene therapy.

Healthy but sedentary individuals show early decline in cellular energy production

A CU Anschutz study reveals reduced mitochondrial efficiency in healthy yet sedentary individuals, which may precede the development of major diseases like cancer, diabetes, and Alzheimer's. Regular exercise acts as a literal shield for cellular health, helping mitochondria seamlessly switch between burning fat and carbohydrates.

SourceUniversity of Colorado Anschutz·JournalClinical Bioenergetics·TypeObservational study·DateJun 29, 2026

Injectable semaglutide shows early promise to improve fertility in women with PMOS

Researchers at the University of Colorado Anschutz have published a proof-of-concept study demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with PMOS, improving both reproductive and metabolic symptoms. The findings suggest that this medication could be a promising therapeutic option for wo...

SourceUniversity of Colorado Anschutz·JournalFertility and Sterility·DateJun 9, 2026

The University of Colorado Anschutz Gates Institute achieves first-in-U.S. FDA clearance for campus-built CAR T-cell therapy

The University of Colorado Anschutz Gates Institute has achieved first-in-U.S. FDA clearance for a novel CAR T-cell therapy targeting aggressive leukemia cells, representing a potential new treatment approach for patients with hard-to-treat disease. The therapy will be evaluated in a Phase 1 clinical trial starting this summer.

Researchers clarify how ketogenic diets treat epilepsy, guiding future therapy development

A new review outlines the scientific explanations behind ketogenic diets' therapeutic benefits for epilepsy, including their ability to strengthen brain energy systems, reduce inflammation, and protect neurons. The review highlights the need for further research, particularly in adults, to develop new therapies that mirror the diet's e...

SourceUniversity of Colorado Anschutz·JournalThe Lancet Neurology·DateMar 11, 2026

Why does chronic back pain make everyday sounds feel harsher? Brain imaging study points to a treatable cause

A new study from CU Anschutz links chronic back pain to heightened brain responses to everyday sounds and finds that Pain Reprocessing Therapy can improve sensory amplification. The research found specific brain changes associated with sound hypersensitivity, which can be treated with psychological therapy.

SourceUniversity of Colorado Anschutz·JournalAnnals of Neurology·DateMar 2, 2026

Regular exercise reduces atrial fibrillation recurrence by nearly 50% after catheter ablation, study shows

A new study from CU Anschutz researchers found that regular physical activity can significantly lower post-ablation atrial fibrillation recurrence risk. Adults who engaged in moderate exercise for 30 minutes three times a week had markedly lower rates of AF recurrence compared to those who were less active.

SourceUniversity of Colorado Anschutz·JournalJournal of Interventional Cardiac Electrophysiology·DateFeb 6, 2026

Brain neuron death occurs throughout life and increases with age, a natural human protein drug may halt neuron death in Alzheimer’s disease

Researchers discovered a link between increasing biomarker levels and cognitive decline, with a potential repurposed drug slowing damage. The study found exponential increases in UCH-L1 and GFAP levels with age, suggesting underlying neuroinflammation may contribute to Alzheimer’s disease.

SourceUniversity of Colorado Anschutz·TypeRandomized controlled/clinical trial·DateDec 19, 2025

Ending federal support for housing first programs could increase U.S. homelessness by 5% in one year, new JAMA study finds

A new study published in JAMA Health Forum estimates that ending federal funding for Housing First programs would result in 44,590 additional people experiencing homelessness within a year, a roughly 5% increase from 2024 levels. This could push tens of thousands of people back into homelessness almost overnight.

SourceUniversity of Colorado Anschutz·JournalJAMA Health Forum·DateDec 19, 2025

New study finds cystic fibrosis drug allows patients to safely scale back lung therapies

A multi-site study led by CU Anschutz researchers found that people with cystic fibrosis who start triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many daily lung treatments while maintaining good health for years. The study showed a steady decline in the use of chronic respiratory therapies, including hype...

SourceUniversity of Colorado Anschutz·JournalJournal of Cystic Fibrosis·DateDec 4, 2025

From lab to clinic: CU Anschutz launches Phase 1 clinical trial of promising combination therapy for resistant ovarian cancer

Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.

SourceUniversity of Colorado Anschutz·JournalCancer Research Communications·DateDec 4, 2025